)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Chosa Oncology
Chosa Oncology (CHOSA) investor relations material
Chosa Oncology Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary27 Aug, 2026
Executive summary
Advanced Platin-DRP® from clinical validation to preparations for commercialization, with strengthened presence in the US and new international collaborations in lung cancer and breast cancer.
Presented significant clinical data at ASCO 2026, including validation of Platin-DRP® in lung and breast cancer, and established a US base in Kendall Square, Boston.
Appointed Bill Cronin to lead US commercialization efforts post-period, aiming to accelerate Platin-DRP® market introduction.
Financial highlights
Net result after financial items for Q2 2026 was -2,632 TSEK, compared to -1,967 TSEK in Q2 2025.
Earnings per share after dilution was -0.03 SEK (Q2 2025: -0.028 SEK).
Cash and cash equivalents as of June 30, 2026, amounted to 2,560 TSEK (June 30, 2025: 1,876 TSEK).
Equity as of June 30, 2026, was 19,107 TSEK (June 30, 2025: 14,467 TSEK).
Directed share issue in February 2026 raised 7.3 MSEK before transaction costs.
Outlook and guidance
Focus for H2 2026 is on translating clinical evidence into commercial value, with ambitions to establish Platin-DRP® as a precision medicine tool for platinum-based cancer therapies.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Chosa Oncology
- Proprietary technology doubles chemo efficacy, with key clinical and partnership milestones ahead.CHOSA
Investor Update - Strategic progress and positive clinical data drive momentum, supported by strengthened finances.CHOSAQ1 2026
- High Platin-DRP® scores predict longer survival for advanced NSCLC patients on platinum chemo.CHOSAStatus update
- Major clinical, financial, and strategic advances drive expanded market potential in oncology.CHOSAQ4 2025
- Significant clinical progress and strengthened financial position with new capital raised in Q3 2025.CHOSAQ3 2025
- Strong Q2 results, clinical progress, and capital raises position for key data in Q3 2025.CHOSAQ2 2025
- Q3 net loss narrowed, financials strengthened, and board expertise expanded with Prof. Hirsch.CHOSAQ3 2024
- Q2 loss narrowed and cash reserves grew as CHOSA advanced oncology partnerships and technology.CHOSAQ2 2024
- DRP® platform expansion and clinical progress drive CHOSA Oncology's Q1 2025 focus.CHOSAQ1 2025
Next Chosa Oncology earnings date
Q3 202619 Nov, 2026
Chosa Oncology
Next Chosa Oncology earnings date
Q3 202619 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Chosa Oncology AB is a Sweden-based biotechnology company focused on the development of innovative cancer therapies. The company specializes in identifying and advancing novel treatment options targeting unmet medical needs in oncology. The company is headquartered in Stockholm, Sweden, and its shares are listed on the Spotlight Stock Market.